SG10201510586PA - Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy - Google Patents

Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy

Info

Publication number
SG10201510586PA
SG10201510586PA SG10201510586PA SG10201510586PA SG10201510586PA SG 10201510586P A SG10201510586P A SG 10201510586PA SG 10201510586P A SG10201510586P A SG 10201510586PA SG 10201510586P A SG10201510586P A SG 10201510586PA SG 10201510586P A SG10201510586P A SG 10201510586PA
Authority
SG
Singapore
Prior art keywords
treatment
eye diseases
combined therapy
excessive neovascularization
neovascularization
Prior art date
Application number
SG10201510586PA
Other languages
English (en)
Inventor
Michael David Schuster
Silviu Itescu
Original Assignee
Mesoblast Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008903349A external-priority patent/AU2008903349A0/en
Application filed by Mesoblast Inc filed Critical Mesoblast Inc
Publication of SG10201510586PA publication Critical patent/SG10201510586PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
SG10201510586PA 2008-06-30 2009-06-29 Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy SG10201510586PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13360708P 2008-06-30 2008-06-30
AU2008903349A AU2008903349A0 (en) 2008-06-30 Treatment of eye diseases and excessive neovascularization using combined therapy

Publications (1)

Publication Number Publication Date
SG10201510586PA true SG10201510586PA (en) 2016-01-28

Family

ID=41507350

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201510586PA SG10201510586PA (en) 2008-06-30 2009-06-29 Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy

Country Status (9)

Country Link
US (1) US20110200612A1 (zh)
EP (1) EP2294184A4 (zh)
JP (2) JP2011526892A (zh)
KR (1) KR20110036101A (zh)
CN (1) CN102076844B (zh)
AU (2) AU2009269149B2 (zh)
CA (1) CA2729303A1 (zh)
SG (1) SG10201510586PA (zh)
WO (1) WO2010005527A1 (zh)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
US20090043365A1 (en) 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US8915253B2 (en) 2005-07-18 2014-12-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US8128674B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8137390B2 (en) 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US8128673B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US9328162B2 (en) * 2010-02-25 2016-05-03 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
CN103826647A (zh) * 2011-07-04 2014-05-28 麦瑟布莱斯特公司 治疗或预防风湿性疾病的方法
AU2012279995C1 (en) 2011-07-06 2019-10-24 Cell Therapy Limited Progenitor cells of mesodermal lineage
FR2983478B1 (fr) 2011-12-01 2013-11-15 Arkema France Procede de preparation d'aminoacide comprenant une etape d'hydroformylation d'un nitrile gras insature
CN103505727A (zh) * 2012-06-28 2014-01-15 中国科学院生物物理研究所 靶向作为vegfr-2共受体cd146的新功能在抗肿瘤血管新生治疗中的应用
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
JP2015528454A (ja) * 2012-08-28 2015-09-28 ノバルティス アーゲー 眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用
KR102506612B1 (ko) * 2012-12-12 2023-03-06 메소블라스트, 아이엔씨. 내피 기능장애 및 염증 질환의 치료
US9763827B2 (en) 2013-04-30 2017-09-19 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
US10092449B2 (en) 2013-04-30 2018-10-09 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
CN105793411B (zh) 2013-11-16 2018-04-17 泰尔茂比司特公司 生物反应器中的细胞扩增
DK3082860T3 (da) * 2013-12-18 2021-01-25 Csl Ltd Fremgangsmåde til behandling af sår
EP3613841B1 (en) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passive replacement of media
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
KR101880790B1 (ko) * 2015-04-07 2018-08-16 서강대학교산학협력단 망막질병 치료를 위한 효과 지속성(Long-term) siRNA 기반 나노메디슨 및 이의 제조방법
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US20170253854A1 (en) * 2016-03-02 2017-09-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of Adipose-Derived Stem Cells for Glaucoma Treatment
EP3464565A4 (en) 2016-05-25 2020-01-01 Terumo BCT, Inc. CELL EXPANSION
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US10974063B2 (en) 2016-06-30 2021-04-13 Alcon Inc. Light therapy for eyelash growth
CN109477110B (zh) * 2016-07-08 2022-11-25 Tak循环株式会社 抑制mex3b基因的表达的核酸、试剂、及疾病的预防或治疗剂
WO2018008750A1 (ja) 2016-07-08 2018-01-11 ＴＡＫ－Ｃｉｒｃｕｌａｔｏｒ株式会社 インターロイキン６、インターロイキン１３、ｔｎｆ、ｇ－ｃｓｆ、ｃｘｃｌ１、ｃｘｃｌ２、又はｃｘｃｌ５に起因する疾病の予防又は治療剤をスクリーニングする方法、及びインターロイキン６、インターロイキン１３、ｔｎｆ、ｇ－ｃｓｆ、ｃｘｃｌ１、ｃｘｃｌ２、又はｃｘｃｌ５に起因する疾病の予防又は治療剤
AU2017301705A1 (en) * 2016-07-26 2019-01-24 North Carolina State University Vector-mediated immune tolerance in the eye
EP3543331A4 (en) 2016-11-15 2020-07-01 Kaneka Corporation CELL POPULATION WITH MESENCHYMAL STEM CELLS FROM FETAL ATTACHMENTS, METHOD FOR THE PRODUCTION THEREOF AND MEDICAL COMPOSITION
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
CN107043699B (zh) * 2017-04-25 2023-04-07 徐子雁 一种低能量激光诱导间充质干细胞血管化的试剂盒
WO2019005737A1 (en) * 2017-06-26 2019-01-03 Amd-Opti, Llc AUTOLOGOUS STEM CELL THERAPIES FOR THE TREATMENT OF OCULAR DISEASE
JP7454379B2 (ja) 2017-12-28 2024-03-22 株式会社カネカ 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物
WO2020141483A1 (en) * 2019-01-03 2020-07-09 Mesoblast International Sàrl Method for improving visual acuity
CN113993527A (zh) 2019-06-14 2022-01-28 株式会社钟化 包含间充质细胞的细胞群、包含其的医药组合物及其制造方法

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089815A (en) 1951-10-11 1963-05-14 Lieb Hans Injectable pharmaceutical preparation, and a method of making same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4983393A (en) 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5858725A (en) 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
JP3591837B2 (ja) 1994-02-17 2004-11-24 ニューヨーク・ブラッド・センター・インコーポレイテッド フィブリン膠およびリポソームを含有する生物学的生体接着剤組成物、その製造方法および使用
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US5643192A (en) 1995-04-06 1997-07-01 Hamilton Civic Hospitals Research Development, Inc. Autologous fibrin glue and methods for its preparation and use
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US20030216335A1 (en) 2001-11-30 2003-11-20 Jennifer Lockridge Method and reagent for the modulation of female reproductive diseases and conditions
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
AU733551B2 (en) 1996-09-25 2001-05-17 Astrazeneca Ab Qinoline derivatives inhibiting the effect of growth factors such as VEGF
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6986890B1 (en) 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
US6162428A (en) 1997-02-12 2000-12-19 Layton Bioscience, Inc. hNT-neuron human neuronal cells to replace ganglion cells
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU2299099A (en) 1998-02-04 1999-08-23 Kyowa Hakko Kogyo Co. Ltd. Antibodies against human vegf receptor kdr
BRPI9908967B1 (pt) 1998-03-20 2017-05-30 Benitec Australia Ltd processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula de planta
CA2325344C (en) 1998-04-08 2017-12-05 Commonwealth Scientific And Industrial Research Organisation Methods and means for obtaining modified phenotypes
US6284245B1 (en) 1998-08-25 2001-09-04 Diacrin, Inc. Neural retinal cells and retinal pigment epithelium cells and their use in treatment of retinal disorders
CA2355896A1 (en) 1998-12-21 2000-06-29 Ludwig Institute For Cancer Research Antibodies to truncated vegf-d and uses thereof
KR20020013942A (ko) 1999-07-01 2002-02-21 우에하라 아끼라 아미노벤조산 유도체
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
ATE398120T1 (de) 1999-11-05 2008-07-15 Astrazeneca Ab Neue quinazolin-derivate
WO2001066127A1 (en) 1999-12-21 2001-09-13 Korea Green Cross Corporation Arginine-rich anti-vascular endothelial growth factor peptides that inhibit growth and metastasis of human tumor cells by blocking angiogenesis
AU783683B2 (en) 2000-01-18 2005-11-24 Vegenics Limited VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
WO2001057067A1 (en) 2000-02-04 2001-08-09 Supratek Pharma Inc. Ligand for vascular endothelial growth factor receptor
AU2001231710A1 (en) 2000-02-09 2001-08-20 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
CN1329390C (zh) 2000-02-15 2007-08-01 苏根公司 吡咯取代的2－二氢吲哚酮蛋白激酶抑制剂
CA2404528A1 (en) 2000-03-31 2001-10-04 Institut Pasteur Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
US6468527B2 (en) 2000-06-22 2002-10-22 Sam L. Austin Biological bioadhesive composition and methods of preparation and use
IL153947A0 (en) 2000-08-09 2003-07-31 Astrazeneca Ab Quinoline derivatives having vegf inhibiting activity
US20030186920A1 (en) 2000-10-13 2003-10-02 Sirois Martin G. Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof
JP2004517631A (ja) 2001-01-17 2004-06-17 ヨウン メー パク クエルセチンにより血管内皮成長因子及びエリスロポエチンの遺伝子発現を阻害する方法
AU2002338313A1 (en) 2001-04-06 2002-10-21 Maxygen Holdings Ltd. Single chain dimeric polypeptides derived from the vegf family
CA2444624A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050222066A1 (en) 2001-05-18 2005-10-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2003070910A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050054596A1 (en) 2001-11-30 2005-03-10 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
CA2461290C (en) * 2001-09-24 2014-11-25 Sangamo Biosciences, Inc. Modulation of stem cells using zinc finger proteins
US6942655B2 (en) 2001-11-13 2005-09-13 Minu, Llc Method to treat age-related macular degeneration
US20040138163A1 (en) 2002-05-29 2004-07-15 Mcswiggen James RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7378246B2 (en) * 2002-02-28 2008-05-27 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for regulating adipogenesis
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US20040121955A1 (en) 2002-04-01 2004-06-24 Mulligan-Kehoe Mary Jo Methods for modulating angiogenesis
US20040005671A1 (en) 2002-05-17 2004-01-08 Amrad Operations Pty Ltd. Immunointeractive molecules
US7824671B2 (en) 2002-10-04 2010-11-02 Tissuetech, Inc. Retinal pigment epithelial cell cultures on amniotic membrane and transplantation
CA2407755A1 (en) * 2002-10-11 2004-04-11 The Hospital For Sick Children Inhibition of vegf secretion
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
KR20050119671A (ko) 2003-04-03 2005-12-21 화이자 인코포레이티드 Ａｇ013736을 포함하는 제형
US20040198798A1 (en) 2003-04-07 2004-10-07 Park Jong-Wan Method for inhibiting tumor angiogenesis and tumor growth
WO2005007828A2 (en) 2003-07-14 2005-01-27 Prolx Pharmaceuticals, Inc. Regulation of hif protein levels via deubiquitination pathways
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
GB0318423D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
US7850959B2 (en) * 2003-10-10 2010-12-14 Beth Israel Deaconess Medical Center Methods and compositions for treating conditions involving abnormal angiogenesis
GB0328021D0 (en) 2003-12-03 2004-01-07 Inst Of Ophthalmology Method
EP2899278A1 (en) 2004-03-12 2015-07-29 Alnylam Pharmaceuticals Inc. iRNA agents targeting VEGF
EP2290074B1 (en) * 2004-05-28 2014-12-17 Asuragen, Inc. Methods and compositions involving microRNA
US7150970B2 (en) 2004-08-02 2006-12-19 University Of Iowa Research Foundation Methods of inhibiting VEGF-C
WO2006023658A2 (en) * 2004-08-17 2006-03-02 Prolx Pharmaceuticals Corp. Method of pre-selecting patients for anti-vegf, anti-hif-1 or anti-thioredoxin therapy
US20060110364A1 (en) 2004-08-20 2006-05-25 Ludwig Institute For Cancer Research Vector-mediated delivery of polynucleotides encoding soluble VEGF receptors
US20080260694A1 (en) 2004-09-24 2008-10-23 Angioblast Systems, Inc. Multipotential Expanded Mesenchymal Precursor Cell Progeny (Memp) and Uses Thereof
WO2006042252A2 (en) * 2004-10-08 2006-04-20 Potentia Pharmeceuticals, Inc. Viral complement control proteins for eye disorders
JP2008520747A (ja) * 2004-11-22 2008-06-19 キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド アデノシンａ３受容体アゴニストを用いたｈｉｆ−１が介在する疾患の促進的治療
CA2598029A1 (en) * 2005-02-24 2006-10-05 The Scripps Research Institute Isolated myeloid-like bone marrow cell populations and methods of treatment therewith
US20070231306A1 (en) * 2005-02-24 2007-10-04 The Scripps Research Institute Isolated myeloid-like cell populations and methods of treatment therewith
ES2654428T3 (es) 2005-04-12 2018-02-13 Mesoblast, Inc. Aislamiento de células multipotenciales adultas por fosfatasa alcalina no específica de tejido
US20060234941A1 (en) 2005-04-15 2006-10-19 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
WO2007013704A1 (en) 2005-07-27 2007-02-01 Juseong College Industry Academy Cooperation Group Recombinant adeno-associated virus comprising antisense cdnas of vegf-a, vegf-b and vegf-c and gene therapeutic agent specific to large intestine cancer, bladder cancer and/or lung cancer comprising the same
US20090215835A1 (en) 2005-10-31 2009-08-27 Scott Wilhelm Treatment of cancer with sorafenib
GB0523810D0 (en) 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
CN100371444C (zh) 2005-12-12 2008-02-27 清华大学深圳研究生院 一种抑制VEGF表达的siRNA及其应用
CN100374573C (zh) 2006-04-14 2008-03-12 中国医学科学院医药生物技术研究所 一种可稳定表达VEGF shRNA的载体pCD-VEGF
US20080089868A1 (en) 2006-04-27 2008-04-17 The Research Foundation Of State University Of New York Retinal stem cell compositions and methods for preparing and using same
WO2007130060A2 (en) 2006-05-03 2007-11-15 Schepens Eye Research Isolation and therapeutic application of adult retinal stem cells collected from extra-retinal tissues
WO2007136673A2 (en) * 2006-05-19 2007-11-29 Medistem Laboratories, Inc. Treatment of disc degenerative disease and compositions for same
WO2007140534A1 (en) 2006-06-08 2007-12-13 Csl Limited Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling
KR100787131B1 (ko) 2006-07-04 2007-12-21 한국생명공학연구원 Ｈｉｆ―１ 활성을 저해하는 화합물, 이의 제조방법 및이를 유효성분으로 함유하는 약학적 조성물
AU2007272313B2 (en) * 2006-07-12 2013-11-21 Mesoblast, Inc. Treatment of excessive neovascularization
KR20090038921A (ko) * 2006-07-31 2009-04-21 바스큘라 바이오제닉스 리미티드 허혈 관련 의학적 증상을 치료하는 폴리펩타이드, 이를 암호화하는 폴리뉴클레오타이드, 및 이의 치료 용도
WO2008031835A2 (en) 2006-09-13 2008-03-20 Novartis Ag Method of treating autoimmune diseases using vegf-pathway inhibitors
WO2008045576A2 (en) 2006-10-12 2008-04-17 Yijia Liu Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
US8277807B2 (en) * 2006-10-12 2012-10-02 Astex Therapeutics Limited Pharmaceutical combinations
JP2010509369A (ja) * 2006-11-10 2010-03-25 ジェネンテック インコーポレイテッド 加齢黄斑変性症を処置するための方法
US20100150911A1 (en) * 2007-02-14 2010-06-17 Opto Global Holdings Pty Ltd Methods and systems of treating age-related macular-degeneration
US8983570B2 (en) * 2007-03-27 2015-03-17 Cardiovascular Biotherapeutics, Inc. Therapeutic angiogenesis for treatment of the spine
US7867724B2 (en) * 2007-11-05 2011-01-11 California Institute Of Technology Compositions and method of treating hypoxia-associated diseases
EP2274006A2 (en) * 2008-03-11 2011-01-19 University Of North Carolina At Chapel Hill Angiostatic compositions comprising truncated tyrosyl-trna synthetase polypeptides and methods of using same
WO2010068794A2 (en) * 2008-12-10 2010-06-17 The General Hospital Corporation Hif inhibitors and use thereof
CN103119063B8 (zh) * 2010-07-07 2016-10-12 土耳其科学技术研究理事会 结合至血管内皮生长因子2（vegfr-2/kdr）上并阻断其活性的重组抗体结构

Also Published As

Publication number Publication date
US20110200612A1 (en) 2011-08-18
KR20110036101A (ko) 2011-04-06
AU2009269149A1 (en) 2010-01-14
JP2011526892A (ja) 2011-10-20
EP2294184A4 (en) 2013-03-06
WO2010005527A1 (en) 2010-01-14
EP2294184A1 (en) 2011-03-16
CN102076844B (zh) 2013-08-07
CN102076844A (zh) 2011-05-25
AU2009269149B2 (en) 2016-03-17
CA2729303A1 (en) 2010-01-14
JP2015038059A (ja) 2015-02-26
AU2016203973A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
SG10201510586PA (en) Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy
IL242268A0 (en) Combinations and forms of administration of therapeutic factors and combined treatment
ZA201106268B (en) Toll-like receptor modulators and treatment of diseases
HK1201046A1 (zh) 治療眼科疾病的方法
ZA201106730B (en) Methods of treatment using combination therapy
IL207014A0 (en) Enhanced delivery of a therapeutic to ocular tissues through iontophoresis
IL229786A (en) Use of inhibitors in the preparation of drugs for the treatment of eye diseases
EP2182983A4 (en) TREATMENT OF AMYLOIDOGENIC DISEASES
HK1173654A1 (zh) 治療化合物及相關的使用方法
HK1129600A1 (zh) 治療過多的新生血管
ZA200906165B (en) Treatment and prevention of neurodegenerative diseases using gene therapy
HK1243436A1 (zh) 特異性配體在msrv相關疾病中的治療用途
EP2624821A4 (en) POLYTHERAPY FOR THE TREATMENT OF DEPRESSION AND OTHER NON-INFECTIOUS DISEASES
EP2710017A4 (en) MACROCYCLIC THERAPEUTIC AGENTS AND METHODS OF TREATMENT
IL214291A (en) Use of Depriferone to prepare a drug to treat and prevent iron-related eye diseases
AU2008903349A0 (en) Treatment of eye diseases and excessive neovascularization using combined therapy
GB201108289D0 (en) Therapeutic garment and method of providing therapy using the same
GB0801511D0 (en) The treatment of ophthalmic diseases
IL231052B (en) Bacteriochlorophyll photosensitizers for the treatment of eye diseases and disorders
GB0901727D0 (en) The treatment of ophthalmic diseases
GB0724970D0 (en) Treatment and prevention of nuerodegenerative diseases
ZA200906883B (en) Methods of treating ophthalmic diseases
GB0700755D0 (en) The Treatment of ophthalmic diseases
GB0920424D0 (en) Therapeutic vaccine for treatment of type 2-diabetes and impaired glucose tolerance
GB0920200D0 (en) Therapeutic vaccine for treatment of type 2-diabetes and impaired glucose tolerance